Avion Wealth’s Jazz Pharmaceuticals JAZZ Stock Holding History

Avion Wealth’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4	Closed	–	–	1187
2023 Q4	$0	Buy	+4	New	+$499	﹤0.01%	1216

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Avion Wealth's JAZZ Position: Q1 2024 in Review

Avion Wealth sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2024, closing a stake of 4 shares.

Avion Wealth first reported a position in JAZZ in Q4 2023 and held it in 1 quarter. The position peaked at $0 in Q4 2023. 480 funds tracked by Wall St. Rank hold JAZZ as of Q1 2024.

Avion Wealth reported no remaining Jazz Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Avion Wealth sold 4 Jazz Pharmaceuticals shares in Q1 2024.
Avion Wealth first reported a position in Jazz Pharmaceuticals in Q4 2023 and held it in 1 quarter.
Avion Wealth's Jazz Pharmaceuticals position peaked at $0 in Q4 2023.
480 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2024.

Based on Avion Wealth's 13F filing for Q1 2024, filed 3 May 2024.